首页> 外文期刊>International Journal of Molecular Sciences >Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis
【24h】

Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis

机译:盐酸Jatrorrhizine抑制RANKL诱导的破骨细胞生成并防止磨损颗粒诱导的溶骨

获取原文
           

摘要

Wear particle-induced aseptic prosthetic loosening is a major complication associated with total joint arthroplasty (TJA). A growing body of evidence suggests that receptor activator of nuclear factor κ-B ligand (RANKL)-stimulated osteoclastogenesis and bone resorption are responsible for peri-implant loosening. Thus, agents which attenuate excessive osteoclast differentiation and function have been considered to offer therapeutic potential for prolonging the life of TJA implants. Jatrorrhizine hydrochloride (JH), a major protoberberine alkaloid isolated from the traditional Chinese herb Coptis chinensis , has been reported to have antimicrobial, antitumor, and antihypercholesterolemic and neuroprotective activities. However, its effects on osteoclast biology remain unknown. Here, we found that JH inhibited RANKL-induced osteoclast formation and bone resorption in vitro and exerted protection against titanium (Ti) particle-induced osteolysis in vivo. Biochemical analysis demonstrated that JH suppressed RANKL-induced activation of MAPKs (p38 and ERK) which down-regulated the production of NFATc1 and NFATc1-regulated osteoclastic marker genes, such as TRAP , CTR and CTSK . Collectively, our findings suggest that JH may be a promising anti-osteoclastogenesis agent for treating periprosthetic osteolysis or other osteoclast-related osteolytic diseases.
机译:磨损颗粒诱导的无菌修复假体松动是与全关节置换术(TJA)相关的主要并发症。越来越多的证据表明,核因子κB配体(RANKL)刺激的破骨细胞生成和骨吸收的受体激活因子是造成种植体周围松弛的原因。因此,已经认为减弱过度的破骨细胞分化和功能的药物具有延长TJA植入物寿命的治疗潜力。据报道,盐酸Jatrorrhizine(JH)是从传统中草药黄连中分离出的主要原小to碱生物碱,具有抗微生物,抗肿瘤以及抗高胆固醇血症和神经保护作用。然而,其对破骨细胞生物学的影响仍然未知。在这里,我们发现JH在体外抑制RANKL诱导的破骨细胞形成和骨吸收,并在体内对钛(Ti)颗粒诱导的骨溶解发挥保护作用。生化分析表明,JH抑制了RANKL诱导的MAPKs激活(p38和ERK),从而下调了NFATc1和NFATc1调控的破骨细胞标记基因(如TRAP,CTR和CTSK)的产生。总体而言,我们的发现表明,JH可能是治疗假体周围溶骨或其他与破骨细胞相关的溶骨性疾病的有希望的抗破骨细胞生成剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号